Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly half of all deaths within five years of an ALD diagnosis were due to liver-related causes.
In 2018, Black and Latino patients with advanced cirrhosis had a higher risk of mortality compared with white people.
Drug-related mortality, including overdose, was the leading cause of death.
People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.
Better results were observed even in people with increased portal hypertension.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
This is according to an analysis of nearly 5,000 Italians recently treated for the virus.
Use of drugs like Nexium or Prilosec is tied to progression to cirrhosis, decompensated cirrhosis and liver cancer in this population.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.